New Logo.png
Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation
October 25, 2022 06:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with James G. Krueger, MD, PhD, Co-director,...
Future Market Insights.png
Interferons Market Projected to Exhibit at a Steady CAGR of 3.9% by 2032 – Future Market Insights, Inc. NEWARK, Del, July 28, 2022 (GLOBE NEWSWIRE) -- As per a latest industry analysis by Future Market Insights, the global interferons market was valued at around US$ 9.1 Bn in 2021 and is anticipated...
TIP_link_300x300.jpg
Virology Market Valuation to Outstrip $5.27Bn by 2028 Growth Projection at 3.6% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
September 21, 2021 08:51 ET | The Insight Partners
New York, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Virology Market: Key InsightsAccording to our latest study on “Virology Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type,...
provectus_logo.jpg
Provectus Names Harold Schmitz, PhD to Company's Scientific Advisory Board
September 11, 2019 07:00 ET | Provectus Biopharmaceuticals Inc.
Dr. Schmitz, General Partner of The March Fund and former Chief Science Officer of Mars, Incorporated is Provectus’ inaugural Scientific Advisory Board member KNOXVILLE, TN, Sept. 11, 2019 (GLOBE...